Clinical Scorecard: Impact of Cyproterone Acetate and Spironolactone on Mammary Development in Transgender Individuals: A Randomized Clinical Study
At a Glance
Category
Detail
Condition
Feminizing hormone therapy in transgender individuals assigned male at birth
Key Mechanisms
Antiandrogens reduce testosterone effects via androgen receptor antagonism and suppression of serum testosterone; cyproterone acetate has progestogenic suppression and more potent androgen receptor antagonism compared to spironolactone
Target Population
Transgender people aged 18+ years commencing feminizing hormone therapy
Care Setting
Outpatient endocrinology clinic
Key Highlights
No significant difference in breast development between cyproterone acetate and spironolactone after 6 months of treatment with estradiol.
Cyproterone acetate more effectively suppresses serum total testosterone concentration to <2 nmol/L compared to spironolactone.
Antiandrogen choice should consider clinician and patient preference and side effect profiles due to similar feminization outcomes.
Guideline-Based Recommendations
Diagnosis
Confirm transgender individuals assigned male at birth seeking feminization and commencing estradiol therapy.
Management
Use standardized estradiol therapy combined with either cyproterone acetate 12.5 mg daily or spironolactone 100 mg daily for antiandrogen effect.
Adjust estradiol dose to achieve serum estradiol concentration of 250 to 600 pmol/L per consensus guidelines.
Monitoring & Follow-up
Measure breast–chest distance and estimated breast volume at baseline, 3 months, and 6 months to assess breast development.
Monitor serum total testosterone concentrations aiming for suppression below 2 nmol/L.
Assess patient-reported gender preoccupation and stability using validated questionnaires such as GPSQ.
Risks
Consider contraindications to spironolactone or cyproterone acetate prior to initiation.
Monitor for side effects related to antiandrogen therapy; choice should balance efficacy and tolerability.
Patient & Prescribing Data
Transgender individuals aged 18 years and older newly commencing feminizing hormone therapy with estradiol.
Both cyproterone acetate and spironolactone combined with estradiol produce similar breast development outcomes over 6 months; cyproterone acetate achieves greater suppression of serum testosterone.
Clinical Best Practices
Individualize antiandrogen selection based on patient preference, side effect profile, and clinical judgment.
Use standardized estradiol dosing protocols with serum estradiol monitoring to optimize feminization.
Employ objective measures such as breast–chest distance and serum testosterone levels to monitor treatment response.
Engage patients in shared decision-making regarding antiandrogen therapy options.
